NEOGENOMICS INC (NEO) Stock Price, Quote, News and Overview
NASDAQ:NEO - Nasdaq - US64049M2098 - Common Stock - Currency: USD
NEO Quote, Performance and Key Statistics
7.55
+0.15 (+2.03%)
The current stock price of NEO is 7.55 USD. In the past month the price increased by 2.3%. In the past year, price decreased by -44.4%.
NEO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| CI | THE CIGNA GROUP | 11.58 | 85.42B | ||
| CVS | CVS HEALTH CORP | 10.6 | 85.30B | ||
| LH | LABCORP HOLDINGS INC | 17.78 | 21.92B | ||
| DGX | QUEST DIAGNOSTICS INC | 19.25 | 19.75B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 14.72 | 16.50B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 124.53 | 13.45B | ||
| DVA | DAVITA INC | 15.43 | 10.76B | ||
| HIMS | HIMS & HERS HEALTH INC | 69.54 | 10.74B | ||
| CHE | CHEMED CORP | 20.08 | 6.92B | ||
| GH | GUARDANT HEALTH INC | N/A | 6.26B | ||
| CRVL | CORVEL CORP | 56.51 | 5.28B | ||
| OPCH | OPTION CARE HEALTH INC | 25.13 | 5.10B |
Related stock screener links
About NEO
Company Profile
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. The company is headquartered in Fort Myers, Florida and currently employs 2,200 full-time employees. The company went IPO on 2012-12-10. The firm offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. The company operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Company Info
NEOGENOMICS INC
9490 Neogenomics Way
Fort Myers FLORIDA 33913 US
CEO: Douglas M. VanOort
Employees: 2200
Phone: 12397680600
NEOGENOMICS INC / NEO FAQ
What is the stock price of NEOGENOMICS INC today?
The current stock price of NEO is 7.55 USD. The price increased by 2.03% in the last trading session.
What is the ticker symbol for NEOGENOMICS INC stock?
The exchange symbol of NEOGENOMICS INC is NEO and it is listed on the Nasdaq exchange.
On which exchange is NEO stock listed?
NEO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEOGENOMICS INC stock?
20 analysts have analysed NEO and the average price target is 11.17 USD. This implies a price increase of 47.99% is expected in the next year compared to the current price of 7.55. Check the NEOGENOMICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEOGENOMICS INC worth?
NEOGENOMICS INC (NEO) has a market capitalization of 971.61M USD. This makes NEO a Small Cap stock.
How many employees does NEOGENOMICS INC have?
NEOGENOMICS INC (NEO) currently has 2200 employees.
What are the support and resistance levels for NEOGENOMICS INC (NEO) stock?
NEOGENOMICS INC (NEO) has a support level at 7.12 and a resistance level at 7.44. Check the full technical report for a detailed analysis of NEO support and resistance levels.
Is NEOGENOMICS INC (NEO) expected to grow?
The Revenue of NEOGENOMICS INC (NEO) is expected to grow by 12.61% in the next year. Check the estimates tab for more information on the NEO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEOGENOMICS INC (NEO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NEO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NEO, evaluating the profitability, health, valuation and growth aspects
- NEOGENOMICS INC (NEO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEOGENOMICS INC (NEO) Sales and EPS estimates to see what analysts future expectations are.
- NEOGENOMICS INC (NEO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEOGENOMICS INC (NEO) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEOGENOMICS INC (NEO) Stock Chart to make your own analysis
- NEOGENOMICS INC (NEO) Latest news and press-releases to stay up to date.
Does NEOGENOMICS INC (NEO) stock pay dividends?
NEO does not pay a dividend.
When does NEOGENOMICS INC (NEO) report earnings?
NEOGENOMICS INC (NEO) will report earnings on 2025-07-28, after the market close.
What is the Price/Earnings (PE) ratio of NEOGENOMICS INC (NEO)?
The PE ratio for NEOGENOMICS INC (NEO) is 62.92. This is based on the reported non-GAAP earnings per share of 0.12 and the current share price of 7.55 USD. Check the full fundamental report for a full analysis of the valuation metrics for NEO.
What is the Short Interest ratio of NEOGENOMICS INC (NEO) stock?
The outstanding short interest for NEOGENOMICS INC (NEO) is 3.39% of its float. Check the ownership tab for more information on the NEO short interest.
NEO Technical Analysis
NEO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NEO. Both the profitability and financial health of NEO have multiple concerns.
NEO Financial Highlights
Over the last trailing twelve months NEO reported a non-GAAP Earnings per Share(EPS) of 0.12. The EPS increased by 400% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.84% | ||
| ROE | -8.73% | ||
| Debt/Equity | 0.38 |
NEO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 77% to NEO. The Buy consensus is the average rating of analysts ratings from 20 analysts.
For the next year, analysts expect an EPS growth of 60.23% and a revenue growth 12.61% for NEO